Immune responses during spontaneous control of HIV and AIDS: what is the hope for a cure?
暂无分享,去创建一个
B. Jacquelin | M. Müller-Trutwin | A. Sáez-Cirión | F. Barré-Sinoussi | A. Saez-Cirion | B. Jacquelin | F. Barré-Sinoussi | M. Müller-Trutwin
[1] M. Lederman,et al. Towards an HIV cure: a global scientific strategy , 2012, Nature Reviews Immunology.
[2] M. Lederman,et al. Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] Xiping Wei,et al. Antiviral pressure exerted by HIV-l-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus , 1997, Nature Medicine.
[4] L. Weinberger,et al. Dramatic Rise in Plasma Viremia after CD8+ T Cell Depletion in Simian Immunodeficiency Virus–infected Macaques , 1999, The Journal of experimental medicine.
[5] C. Hallahan,et al. Maintenance of Large Numbers of Virus-Specific CD8+ T Cells in HIV-Infected Progressors and Long-Term Nonprogressors , 2000, The Journal of Immunology.
[6] Chaim A. Schramm,et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus , 2013, Nature.
[7] L. Morris,et al. The Antibody Response against HIV-1. , 2012, Cold Spring Harbor perspectives in medicine.
[8] L. Picker,et al. IL-2, IL-7 and IL-15 as immuno-modulators during SIV/HIV vaccination and treatment. , 2009, Current HIV research.
[9] J. Montaner,et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. , 2004, The New England journal of medicine.
[10] R. Johnson,et al. Sooty mangabeys and rhesus macaques exhibit significant divergent natural killer cell responses during both acute and chronic phases of SIV infection. , 2008, Cellular immunology.
[11] M. Müller-Trutwin,et al. Role for plasmacytoid dendritic cells in anti‐HIV innate immunity , 2005, Immunology and cell biology.
[12] O. Lambotte,et al. HIV Controller CD4+ T Cells Respond to Minimal Amounts of Gag Antigen Due to High TCR Avidity , 2010, PLoS pathogens.
[13] V. Appay. The physiological role of cytotoxic CD4+ T‐cells: the holy grail? , 2004, Clinical and experimental immunology.
[14] M. Lederman,et al. Interleukin-7 promotes HIV persistence during antiretroviral therapy. , 2013, Blood.
[15] C. Rouzioux,et al. Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy , 2001, AIDS.
[16] Jerome H. Kim,et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.
[17] Feng Gao,et al. Phenotypic properties of transmitted founder HIV-1 , 2013, Proceedings of the National Academy of Sciences.
[18] Steven M. Wolinsky,et al. Relative resistance to HIV–1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high–risk sexual exposures , 1996, Nature Medicine.
[19] D. Richman,et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. , 2013, The New England journal of medicine.
[20] H. Hatano. Immune activation and HIV persistence: considerations for novel therapeutic interventions , 2013, Current opinion in HIV and AIDS.
[21] Brigitte Autran,et al. Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study , 2013, PLoS pathogens.
[22] Steven G. Deeks,et al. HLA Class I-Restricted T-Cell Responses May Contribute to the Control of Human Immunodeficiency Virus Infection, but Such Responses Are Not Always Necessary for Long-Term Virus Control , 2008, Journal of Virology.
[23] Baek Kim,et al. p21-mediated RNR2 repression restricts HIV-1 replication in macrophages by inhibiting dNTP biosynthesis pathway , 2013, Proceedings of the National Academy of Sciences.
[24] M. Dierich,et al. Complement-HIV interactions during all steps of viral pathogenesis. , 2008, Vaccine.
[25] C. Rouzioux,et al. Alpha interferon administration during structured interruptions of combination antiretroviral therapy in patients with chronic HIV-1 infection: INTERVAC ANRS 105 trial , 2011, AIDS.
[26] Ashley T. Haase,et al. Targeting early infection to prevent HIV-1 mucosal transmission , 2010, Nature.
[27] H. Schuitemaker,et al. Low Immune Activation despite High Levels of Pathogenic Human Immunodeficiency Virus Type 1 Results in Long-Term Asymptomatic Disease , 2007, Journal of Virology.
[28] Hendrik Streeck,et al. Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. , 2005, Blood.
[29] R. Lempicki,et al. Evidence for innate immune system activation in HIV type 1-infected elite controllers. , 2014, The Journal of infectious diseases.
[30] D. Montefiori,et al. Functional Cure of SIVagm Infection in Rhesus Macaques Results in Complete Recovery of CD4+ T Cells and Is Reverted by CD8+ Cell Depletion , 2011, PLoS pathogens.
[31] H. Agut,et al. HIV type 1-specific IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of long-term nonprogression. , 2001, AIDS research and human retroviruses.
[32] Jeffrey N. Martin,et al. Prospective Antiretroviral Treatment of Asymptomatic, HIV-1 Infected Controllers , 2013, PLoS pathogens.
[33] P. Tebas,et al. Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir. , 1999, AIDS.
[34] Charles R. Brown,et al. Plateau Levels of Viremia Correlate with the Degree of CD4+-T-Cell Loss in Simian Immunodeficiency Virus SIVagm-Infected Pigtailed Macaques: Variable Pathogenicity of Natural SIVagm Isolates , 2005, Journal of Virology.
[35] M. Gardner,et al. Human alpha- and beta-interferon but not gamma- suppress the in vitro replication of LAV, HTLV-III, and ARV-2. , 1986, Journal of interferon research.
[36] R. Kaul,et al. HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. , 1999, AIDS.
[37] H. Ding,et al. Relative resistance of HIV-1 founder viruses to control by interferon-alpha , 2013, Retrovirology.
[38] A. Bergamaschi,et al. Human TRIM Gene Expression in Response to Interferons , 2009, PloS one.
[39] Jack T Stapleton,et al. The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation , 2010, Science.
[40] Todd M. Allen,et al. TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection , 2012, Nature Immunology.
[41] Rachel E. Owen,et al. HIV+ elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responses , 2010, AIDS.
[42] M. Malim,et al. Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection , 2013, Nature.
[43] F. Pereyra,et al. Leukocyte Immunoglobulin-Like Receptors Maintain Unique Antigen-Presenting Properties of Circulating Myeloid Dendritic Cells in HIV-1-Infected Elite Controllers , 2010, Journal of Virology.
[44] R. Steinman,et al. Dendritic cell‐targeted protein vaccines: a novel approach to induce T‐cell immunity , 2012, Journal of internal medicine.
[45] F. Pereyra,et al. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers , 2012, AIDS.
[46] M. Carrington,et al. Impact of protective killer inhibitory receptor/human leukocyte antigen genotypes on natural killer cell and T-cell function in HIV-1-infected controllers , 2012, AIDS.
[47] C. Rouzioux,et al. CD4 Dynamics over a 15 Year-Period among HIV Controllers Enrolled in the ANRS French Observatory , 2011, PloS one.
[48] H. Clifford Lane,et al. Administration of an Anti-CD8 Monoclonal Antibody Interferes with the Clearance of Chimeric Simian/Human Immunodeficiency Virus during Primary Infections of Rhesus Macaques , 1998, Journal of Virology.
[49] B. Clotet,et al. A Dendritic Cell–Based Vaccine Elicits T Cell Responses Associated with Control of HIV-1 Replication , 2013, Science Translational Medicine.
[50] Asier Sáez-Cirión,et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype , 2007, Proceedings of the National Academy of Sciences.
[51] R. Ribeiro,et al. Kinetics of Myeloid Dendritic Cell Trafficking and Activation: Impact on Progressive, Nonprogressive and Controlled SIV Infections , 2013, PLoS pathogens.
[52] M. Carrington,et al. Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. , 2013, The Journal of infectious diseases.
[53] L. Stamatatos,et al. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies , 2013, The Journal of experimental medicine.
[54] F. Pereyra,et al. Elite Controllers with Low to Absent Effector CD8+ T Cell Responses Maintain Highly Functional, Broadly Directed Central Memory Responses , 2012, Journal of Virology.
[55] D. Scott‐Algara,et al. Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in HIV-exposed uninfected individuals. , 2007, Blood.
[56] H. Stein,et al. Mucosal but not peripheral FOXP3+ regulatory T cells are highly increased in untreated HIV infection and normalize after suppressive HAART. , 2006, Blood.
[57] Jeffrey N. Martin,et al. Evidence for Persistent Low-Level Viremia in Individuals Who Control Human Immunodeficiency Virus in the Absence of Antiretroviral Therapy , 2008, Journal of Virology.
[58] Hui Li,et al. Nef-Mediated Suppression of T Cell Activation Was Lost in a Lentiviral Lineage that Gave Rise to HIV-1 , 2006, Cell.
[59] Lynn Morris,et al. Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape , 2012, Nature Medicine.
[60] P. Easterbrook,et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[61] Jerome H. Kim,et al. Impact of Multi-Targeted Antiretroviral Treatment on Gut T Cell Depletion and HIV Reservoir Seeding during Acute HIV Infection , 2012, PloS one.
[62] E. Rosenberg,et al. Evolution of innate and adaptive effector cell functions during acute HIV-1 infection. , 2007, The Journal of infectious diseases.
[63] M. Brameier,et al. In Vivo Administration of a JAK3 Inhibitor during Acute SIV Infection Leads to Significant Increases in Viral Load during Chronic Infection , 2014, PLoS pathogens.
[64] P. Sansonetti,et al. Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS. , 1995, AIDS research and human retroviruses.
[65] J. Levy,et al. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. , 1986, Science.
[66] S. Oka,et al. Strong Ability of Nef-Specific CD4+ Cytotoxic T Cells To Suppress Human Immunodeficiency Virus Type 1 (HIV-1) Replication in HIV-1-Infected CD4+ T Cells and Macrophages , 2009, Journal of Virology.
[67] J. Fellay,et al. Role of retroviral restriction factors in the interferon-α–mediated suppression of HIV-1 in vivo , 2012, Proceedings of the National Academy of Sciences.
[68] C. Bailey-Kellogg,et al. Divergent Antibody Subclass and Specificity Profiles but Not Protective HLA-B Alleles Are Associated with Variable Antibody Effector Function among HIV-1 Controllers , 2013, Journal of Virology.
[69] J. van Grevenynghe,et al. Profound metabolic, functional, and cytolytic differences characterize HIV-specific CD8 T cells in primary and chronic HIV infection. , 2012, Blood.
[70] P. Morlat,et al. Early evolution of plasma soluble TNF-alpha p75 receptor as a marker of progression in treated HIV-infected patients. , 2008, AIDS research and human retroviruses.
[71] M. Altfeld,et al. Evasion from NK cell-mediated immune responses by HIV-1. , 2012, Microbes and infection.
[72] Terri Wrin,et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. , 2008, The Journal of infectious diseases.
[73] Victor Appay,et al. A molecular basis for the control of preimmune escape variants by HIV-specific CD8+ T cells. , 2013, Immunity.
[74] Michael Y. Gerner,et al. CD4 T follicular helper cell dynamics during SIV infection. , 2012, The Journal of clinical investigation.
[75] Fan Wu,et al. TRIM5 alpha Drives SIVsmm Evolution in Rhesus Macaques , 2013, PLoS pathogens.
[76] F. Barré-Sinoussi,et al. Acute Plasma Biomarkers of T Cell Activation Set-Point Levels and of Disease Progression in HIV-1 Infection , 2012, PloS one.
[77] Jeffrey N. Martin,et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. , 2008, The Journal of infectious diseases.
[78] D. Douek,et al. Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts , 2009, Nature Medicine.
[79] E. Rosenberg,et al. Dendritic cell dysfunction during primary HIV-1 infection. , 2011, The Journal of infectious diseases.
[80] David Nemazee,et al. Rational immunogen design to target specific germline B cell receptors , 2012, Retrovirology.
[81] L. Mayer,et al. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. , 1995, Clinical therapeutics.
[82] J. Piccirillo,et al. HLA alleles determine differences in human natural killer cell responsiveness and potency , 2008, Proceedings of the National Academy of Sciences.
[83] E. Rosenberg,et al. HIV-Specific Cytolytic CD4 T Cell Responses During Acute HIV Infection Predict Disease Outcome , 2012, Science Translational Medicine.
[84] M. Paiardini,et al. HIV‐associated chronic immune activation , 2013, Immunological reviews.
[85] B. Autran,et al. Maraviroc-induced decrease in circulating bacterial products is not linked to an increase in immune activation in HIV-infected individuals. , 2013, Blood.
[86] J. Tschopp,et al. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways , 1994, Nature.
[87] B. Walker,et al. Matrix Metalloprotease Inhibitors Restore Impaired NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Human Immunodeficiency Virus Type 1 Infection , 2009, Journal of Virology.
[88] E. Zúñiga,et al. Persistent virus infection inhibits type I interferon production by plasmacytoid dendritic cells to facilitate opportunistic infections. , 2008, Cell host & microbe.
[89] M. Rosińska,et al. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. , 2012, Archives of internal medicine.
[90] Qingsheng Li,et al. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells , 2005, Nature.
[91] Robert F. Siliciano,et al. Role of Natural Killer Cells in a Cohort of Elite Suppressors: Low Frequency of the Protective KIR3DS1 Allele and Limited Inhibition of Human Immunodeficiency Virus Type 1 Replication In Vitro , 2009, Journal of Virology.
[92] Martin Meier-Schellersheim,et al. CD4 T Cell Depletion Is Linked Directly to Immune Activation in the Pathogenesis of HIV-1 and HIV-2 but Only Indirectly to the Viral Load1 , 2002, The Journal of Immunology.
[93] D. Kaufmann,et al. Role of PD-1 in HIV Pathogenesis and as Target for Therapy , 2012, Current HIV/AIDS Reports.
[94] E. Riley,et al. Differential Induction of TGF-β Regulates Proinflammatory Cytokine Production and Determines the Outcome of Lethal and Nonlethal Plasmodium yoelii Infections 1 , 2003, The Journal of Immunology.
[95] M. Altfeld,et al. Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine , 2011, AIDS.
[96] C. Rouzioux,et al. Spontaneous control of viral replication during primary HIV infection: when is "HIV controller" status established? , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[97] Jerome H. Kim,et al. Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys , 2013, Cell.
[98] J. Chermann,et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). , 1983, Science.
[99] H. Schuitemaker,et al. The effecT of TrIm 5 PolymorPhIsms on The clInIcal course of hIV-1 InfecTIon , 2011 .
[100] M. Kruhlak,et al. Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[101] A. Bergamaschi,et al. Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers. , 2011, Blood.
[102] Jeffrey N. Martin,et al. HIV Controllers with HLA-DRB1*13 and HLA-DQB1*06 Alleles Have Strong, Polyfunctional Mucosal CD4+ T-Cell Responses , 2010, Journal of Virology.
[103] J. Lifson,et al. Differential infection patterns of CD4+ T cells and lymphoid tissue viral burden distinguish progressive and nonprogressive lentiviral infections. , 2012, Blood.
[104] E. Wherry,et al. Acquired transcriptional programming in functional and exhausted virus-specific CD8 T cells. , 2012, Current opinion in HIV and AIDS.
[105] Jeffrey N. Martin,et al. A Low T Regulatory Cell Response May Contribute to Both Viral Control and Generalized Immune Activation in HIV Controllers , 2011, PloS one.
[106] Matthew S. Lewis,et al. Cytomegalovirus Vectors Violate CD8+ T Cell Epitope Recognition Paradigms , 2013, Science.
[107] G. Pantaleo,et al. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production , 2013, The Journal of experimental medicine.
[108] M. Dietrich,et al. Lymphatic tissue changes in AIDS and other retrovirus infections: tools and insights. , 1990, Lymphology.
[109] Pamela Warner,et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand , 2010, Journal of Family Planning and Reproductive Health Care.
[110] A. Fauci,et al. Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines. , 1989, Science.
[111] J. Schmitz,et al. A nonhuman primate model for the selective elimination of CD8+ lymphocytes using a mouse-human chimeric monoclonal antibody. , 1999, The American journal of pathology.
[112] S. Boni,et al. Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation , 2013, Proceedings of the National Academy of Sciences.
[113] F. Barré-Sinoussi,et al. Plasmacytoid Dendritic Cell Dynamics and Alpha Interferon Production during Simian Immunodeficiency Virus Infection with a Nonpathogenic Outcome , 2008, Journal of Virology.
[114] Jeffrey N. Martin,et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis , 2009, AIDS.
[115] P. Roques,et al. Effect of a short-term HAART on SIV load in macaque tissues is dependent on time of initiation and antiviral diffusion , 2010, Retrovirology.
[116] A. Blancher,et al. Influence of the MHC genotype on the progression of experimental SIV infection in the Mauritian cynomolgus macaque , 2011, Immunogenetics.
[117] E. Rosenberg,et al. Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[118] Michael S. Seaman,et al. Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys , 2013, Nature.
[119] Charles M. Rice,et al. MX2 is an interferon-induced inhibitor of HIV-1 infection , 2013, Nature.
[120] David Heckerman,et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load , 2007, Nature Medicine.
[121] V. Simon,et al. APOBEC3G Polymorphism as a Selective Barrier to Cross-Species Transmission and Emergence of Pathogenic SIV and AIDS in a Primate Host , 2013, PLoS pathogens.
[122] F. Barré-Sinoussi,et al. Persistent resistance to HIV-1 infection in CD4 T cells from exposed uninfected Vietnamese individuals is mediated by entry and post-entry blocks , 2006, Retrovirology.
[123] Thierry Prazuck,et al. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection , 2010, AIDS.
[124] Myron S. Cohen,et al. Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. , 2011, The Journal of infectious diseases.
[125] O. Lambotte,et al. HIV Controllers Maintain a Population of Highly Efficient Th1 Effector Cells in Contrast to Patients Treated in the Long Term , 2012, Journal of Virology.
[126] C. Hallahan,et al. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. , 2008, Immunity.
[127] J. Mellors,et al. Nonhuman Primate Models for HIV Cure Research , 2012, PLoS pathogens.
[128] Amalio Telenti,et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1 , 2007, Nature Genetics.
[129] F. Pereyra,et al. Preserved function of regulatory T cells in chronic HIV-1 infection despite decreased numbers in blood and tissue. , 2012, The Journal of infectious diseases.
[130] Mario Roederer,et al. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection , 2005, Nature.
[131] H. Liao,et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers , 2009, AIDS.
[132] V. Maino,et al. Insufficient Production and Tissue Delivery of CD4+Memory T Cells in Rapidly Progressive Simian Immunodeficiency Virus Infection , 2004, The Journal of experimental medicine.
[133] Hui Li,et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection , 2008, Proceedings of the National Academy of Sciences.
[134] B. Vuylsteke,et al. Cutting Edge: Resistance to HIV-1 Infection among African Female Sex Workers Is Associated with Inhibitory KIR in the Absence of Their HLA Ligands1 , 2006, The Journal of Immunology.
[135] R. Zinkernagel,et al. CD8+ T cell‐mediated protection against an intracellular bacterium by perforin‐dependent cytotoxicity , 1994, European journal of immunology.
[136] R. Siliciano,et al. Challenges in Detecting HIV Persistence during Potentially Curative Interventions: A Study of the Berlin Patient , 2013, PLoS pathogens.
[137] S. Heath,et al. Exhaustive genotyping of the CEM15 (APOBEC3G) gene and absence of association with AIDS progression in a French cohort. , 2005, The Journal of infectious diseases.
[138] Jaranit Kaewkungwal,et al. The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope , 2012, The Journal of Immunology.
[139] D. Kitch,et al. Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[140] A. Sáez-Cirión,et al. HIV controllers: a genetically determined or inducible phenotype? , 2013, Immunological reviews.
[141] Jeff E. Mold,et al. Tryptophan Catabolism by Indoleamine 2,3-Dioxygenase 1 Alters the Balance of TH17 to Regulatory T Cells in HIV Disease , 2010, Science Translational Medicine.
[142] A. Trkola,et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies , 2005, Nature Medicine.
[143] Matthew S. Lewis,et al. Profound early control of highly pathogenic SIV by an effector-memory T cell vaccine , 2011, Nature.
[144] Zhiwei Chen,et al. PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8+ T cells in mice. , 2013, The Journal of clinical investigation.
[145] B. Clotet,et al. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection , 2014, AIDS.
[146] Jeffrey N. Martin,et al. Epistatic interactions between Fc (GM) and FcγR genes and the host control of human immunodeficiency virus replication. , 2012, Human immunology.
[147] E. Ruiz-Mateos,et al. Plasmacytoid Dendritic Cells Reduce HIV Production in Elite Controllers , 2012, Journal of Virology.
[148] F. Miedema,et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS , 2003, AIDS.
[149] R. Siliciano,et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. , 2012, Immunity.
[150] I. Sereti,et al. Can early therapy reduce inflammation? , 2014, Current opinion in HIV and AIDS.
[151] R. Johnson,et al. SIV infection induces accumulation of plasmacytoid dendritic cells in the gut mucosa. , 2012, The Journal of infectious diseases.
[152] Zhiwei Chen,et al. PD 1-based DNA vaccine amplifies HIV-1 GAG-specific CD 8 + T cells in mice , 2013 .
[153] A. Della Corte,et al. A Highly Intensified ART Regimen Induces Long-Term Viral Suppression and Restriction of the Viral Reservoir in a Simian AIDS Model , 2012, PLoS pathogens.
[154] R. Schooley,et al. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. , 2010, The Journal of infectious diseases.
[155] K. Reimann,et al. Blocking of α4β7 Gut-Homing Integrin during Acute Infection Leads to Decreased Plasma and Gastrointestinal Tissue Viral Loads in Simian Immunodeficiency Virus-Infected Rhesus Macaques , 2011, The Journal of Immunology.
[156] C. Passaes,et al. HIV cure research: advances and prospects. , 2014, Virology.
[157] G. Dickson,et al. Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1 , 2009, Proceedings of the National Academy of Sciences.
[158] E. Ruiz-Mateos,et al. Plasmacytoid dendritic cells (pDCs) from HIV controllers produce interferon-α and differentiate into functional killer pDCs under HIV activation. , 2012, The Journal of infectious diseases.
[159] Eric Delwart,et al. Homogeneous quasispecies in 16 out of 17 individuals during very early HIV-1 primary infection , 2002, AIDS.
[160] C. Rouzioux,et al. Undetectable viremia without antiretroviral therapy in patients with HIV seroconversion: an uncommon phenomenon? , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[161] Keith Hoots,et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS , 2002, Nature Genetics.
[162] Tao Dong,et al. Immune Activation and CD8+ T-Cell Differentiation towards Senescence in HIV-1 Infection , 2004, PLoS biology.
[163] D. Douek,et al. Reduction of Immune Activation with Chloroquine Therapy during Chronic HIV Infection , 2010, Journal of Virology.
[164] F. Marincola,et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[165] R. Phillips,et al. HIV-1-specific CD4+ responses in primary HIV-1 infection predict disease progression , 2014, AIDS.
[166] F. Barré-Sinoussi,et al. Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS. , 2005, The Journal of clinical investigation.
[167] M. Betts,et al. Flow cytometric detection of perforin upregulation in human CD8 T cells , 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[168] C. Larsen,et al. Statin Therapy and Mortality in HIV-Infected Individuals; A Danish Nationwide Population-Based Cohort Study , 2013, PloS one.
[169] A. Bergamaschi,et al. The CDK Inhibitor p21Cip1/WAF1 Is Induced by FcγR Activation and Restricts the Replication of Human Immunodeficiency Virus Type 1 and Related Primate Lentiviruses in Human Macrophages , 2009, Journal of Virology.
[170] Lewis H Kuller,et al. Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection , 2008, PLoS medicine.
[171] G. Carcelain,et al. Immune responses driven by protective human leukocyte antigen alleles from long-term nonprogressors are associated with low HIV reservoir in central memory CD4 T cells. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[172] Galit Alter,et al. HLA Class I Subtype-Dependent Expansion of KIR3DS1+ and KIR3DL1+ NK Cells during Acute Human Immunodeficiency Virus Type 1 Infection , 2009, Journal of Virology.
[173] R. König,et al. SAMHD1-Deficient CD14+ Cells from Individuals with Aicardi-Goutières Syndrome Are Highly Susceptible to HIV-1 Infection , 2011, PLoS pathogens.
[174] J. Routy,et al. Increased proportion of KIR3DS1 homozygotes in HIV-exposed uninfected individuals , 2008, AIDS.
[175] R. D’Aquila,et al. Lower HIV Provirus Levels Are Associated with More APOBEC3G Protein in Blood Resting Memory CD4+ T Lymphocytes of Controllers In Vivo , 2013, PloS one.
[176] D. Douek. Immune activation, HIV persistence, and the cure. , 2013, Topics in antiviral medicine.
[177] D. Ho,et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome , 1994, Journal of virology.
[178] F. Barré-Sinoussi,et al. High Levels of Viral Replication during Primary Simian Immunodeficiency Virus SIVagm Infection Are Rapidly and Strongly Controlled in African Green Monkeys , 2000, Journal of Virology.
[179] C. Rouzioux,et al. Heterogeneity in HIV Suppression by CD8 T Cells from HIV Controllers: Association with Gag-Specific CD8 T Cell Responses1 , 2009, The Journal of Immunology.
[180] C. Rouzioux,et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. , 2009, The Journal of clinical investigation.
[181] M. Dierich,et al. Antibodies attenuate the capacity of dendritic cells to stimulate HIV-specific cytotoxic T lymphocytes. , 2012, The Journal of allergy and clinical immunology.
[182] Jerome H. Kim,et al. Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family , 2012, Journal of Virology.
[183] T. Elliott,et al. Peptide antagonism as a mechanism for NK cell activation , 2010, Proceedings of the National Academy of Sciences.
[184] R. Center,et al. Isotype-switched immunoglobulin G antibodies to HIV Gag proteins may provide alternative or additional immune responses to ‘protective’ human leukocyte antigen-B alleles in HIV controllers , 2013, AIDS.
[185] G. Silvestri,et al. Nonhuman primate models in AIDS research , 2013, Current opinion in HIV and AIDS.
[186] Jeffrey N. Martin,et al. Phenotypic, Functional, and Kinetic Parameters Associated with Apparent T-Cell Control of Human Immunodeficiency Virus Replication in Individuals with and without Antiretroviral Treatment , 2005, Journal of Virology.
[187] D. Watkins,et al. Gag-Specific CD8+ T Lymphocytes Recognize Infected Cells before AIDS-Virus Integration and Viral Protein Expression1 , 2007, The Journal of Immunology.
[188] C. Rouzioux,et al. Continuous versus intermittent treatment strategies during primary HIV-1 infection: the randomized ANRS INTERPRIM Trial , 2012, AIDS.
[189] E. Rosenberg,et al. Transcriptional Profiling of Cd4 T Cells Identifies Distinct Subgroups of Hiv-1 Elite Controllers , 2022 .
[190] G. Freeman,et al. PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. , 2012, The Journal of clinical investigation.
[191] Guido Ferrari,et al. Cross-Sectional Detection of Acute HIV Infection: Timing of Transmission, Inflammation and Antiretroviral Therapy , 2011, PloS one.
[192] C. Chougnet,et al. Increased IFN-gamma production by NK and CD3+/CD56+ cells in sexually HIV-1-exposed but uninfected individuals. , 2006, Clinical immunology.
[193] T. Hirbod,et al. Mucosal immune responses in the genital tract of HIV‐1‐exposed uninfected women , 2007, Journal of internal medicine.
[194] J. Heeney,et al. Prevention of SIV Rectal Transmission and Priming of T Cell Responses in Macaques after Local Pre-exposure Application of Tenofovir Gel , 2008, PLoS medicine.
[195] D. Watkins,et al. Gag-Specific CD 8 T Lymphocytes Recognize Infected Cells before AIDS-Virus Integration and Viral Protein Expression 1 , 2007 .
[196] C. Hallahan,et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors , 2002, Nature Immunology.
[197] M. Lederman,et al. Response: Maraviroc intensification and microbial translocation. , 2013, Blood.
[198] M. Carrington,et al. Cutting Edge: Allele-Specific and Peptide-Dependent Interactions between KIR3DL1 and HLA-A and HLA-B12 , 2007, The Journal of Immunology.
[199] E. Rosenberg,et al. CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. , 2011, The Journal of clinical investigation.
[200] Mario Roederer,et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. , 2006, Blood.
[201] R. Desrosiers,et al. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. , 1992, Science.
[202] Kristen K. Dang,et al. Genome-Wide mRNA Expression Correlates of Viral Control in CD4+ T-Cells from HIV-1-Infected Individuals , 2010, PLoS pathogens.
[203] J. Schmitz,et al. Natural SIV Infection: Immunological Aspects , 2012 .
[204] A. Ejaz,et al. Complement as an Endogenous Adjuvant for Dendritic Cell-Mediated Induction of Retrovirus-Specific CTLs , 2010, PLoS pathogens.
[205] C. Rouzioux,et al. CD8 T-Cells from Most HIV-Infected Patients Lack Ex Vivo HIV-Suppressive Capacity during Acute and Early Infection , 2013, PloS one.
[206] J Darbyshire,et al. CD4+ count-guided interruption of antiretroviral treatment. , 2006, The New England journal of medicine.
[207] K. Lichtenstein,et al. Statin Use Is Associated With Incident Diabetes Mellitus Among Patients in the HIV Outpatient Study , 2015, Journal of acquired immune deficiency syndromes.
[208] D. Scott‐Algara,et al. Preserved Central Memory and Activated Effector Memory CD4+ T-Cell Subsets in Human Immunodeficiency Virus Controllers: an ANRS EP36 Study , 2007, Journal of Virology.
[209] Z. Grossman,et al. HIV preferentially infects HIV-specific CD4+ T cells , 2002, Nature.
[210] J V Giorgi,et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. , 1999, The Journal of infectious diseases.
[211] O. Lambotte,et al. Early and long-lasting alteration of effector CD45RA(-)Foxp3(high) regulatory T-cell homeostasis during HIV infection. , 2012, The Journal of infectious diseases.
[212] S. Coppens,et al. Immune and Viral Correlates of “Secondary Viral Control” after Treatment Interruption in Chronically HIV-1 Infected Patients , 2012, PloS one.
[213] D. Scott‐Algara,et al. Cutting Edge: Increased NK Cell Activity in HIV-1-Exposed but Uninfected Vietnamese Intravascular Drug Users 1 , 2003, The Journal of Immunology.
[214] L. Weiss,et al. The split personality of regulatory T cells in HIV infection. , 2013, Blood.
[215] E. Thiel,et al. Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. , 2011, Blood.
[216] M. Lederman,et al. Effects of Recombinant Human Interleukin 7 on T-Cell Recovery and Thymic Output in HIV-Infected Patients Receiving Antiretroviral Therapy: Results of a Phase I/IIa Randomized, Placebo-Controlled, Multicenter Study , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[217] K. Harada,et al. Direct Observation of Vortex Dynamics in Superconducting Films with Regular Arrays of Defects , 1996, Science.
[218] R. Schooley,et al. Safety , Tolerability , and Mechanisms of Antiretroviral Activity of Pegylated Interferon Alfa-2 a in HIV-1 – Monoinfected Participants : A Phase II Clinical Trial , 2010 .
[219] F. Barré-Sinoussi,et al. African non human primates infected by SIV - why don't they get sick? Lessons from studies on the early phase of non-pathogenic SIV infection. , 2009, Current HIV research.
[220] F. Barré-Sinoussi,et al. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. , 2009, The Journal of clinical investigation.
[221] H. Schuitemaker,et al. The Effect of Trim5 Polymorphisms on the Clinical Course of HIV-1 Infection , 2008, PLoS pathogens.
[222] Y. Seo,et al. Type I Interferon Modulates the Battle of Host Immune System Against Viruses , 2010, Advances in Applied Microbiology.
[223] G. Freeman,et al. Enhancing SIV-Specific Immunity In Vivo by PD-1 Blockade , 2008, Nature.
[224] S. Lank,et al. Major Histocompatibility Complex Class I Haplotype Diversity in Chinese Rhesus Macaques , 2013, G3: Genes, Genomes, Genetics.
[225] Aarti Gautam,et al. Cutting Edge: Experimentally Induced Immune Activation in Natural Hosts of Simian Immunodeficiency Virus Induces Significant Increases in Viral Replication and CD4+ T Cell Depletion1 , 2008, The Journal of Immunology.
[226] S. Arya,et al. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. , 1995, Science.
[227] A. Landay,et al. Chloroquine Modulates HIV-1-Induced Plasmacytoid Dendritic Cell Alpha Interferon: Implication for T-Cell Activation , 2009, Antimicrobial Agents and Chemotherapy.
[228] M. Malim,et al. HIV Restriction Factors and Mechanisms of Evasion. , 2012, Cold Spring Harbor perspectives in medicine.
[229] G. Boucher,et al. Transcription factor FOXO3a controls the persistence of memory CD4+ T cells during HIV infection , 2008, Nature Medicine.
[230] B. Walker,et al. Fitness Cost of Escape Mutations in p24 Gag in Association with Control of Human Immunodeficiency Virus Type 1 , 2006, Journal of Virology.
[231] S. Rowland-Jones,et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes , 2001, Nature.
[232] T. Ndung’u,et al. Human TRIM5alpha expression levels and reduced susceptibility to HIV-1 infection. , 2009, The Journal of infectious diseases.
[233] J. van Lunzen,et al. Expansion of HIV-specific T follicular helper cells in chronic HIV infection. , 2012, The Journal of clinical investigation.
[234] B. Gazzard,et al. Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial. , 2012, JAMA.
[235] L. Picker,et al. Profound CD4+/CCR5+ T cell expansion is induced by CD8+ lymphocyte depletion but does not account for accelerated SIV pathogenesis , 2009, The Journal of experimental medicine.
[236] M. Proschan,et al. B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. , 2010, Blood.
[237] J. Mascola,et al. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. , 2012, Immunity.
[238] M. Lederman,et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection , 2006, Nature Medicine.
[239] R. Chow,et al. Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. , 1997, Clinical therapeutics.
[240] S. Arya,et al. Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.
[241] J. Hiscott,et al. Intact Type I Interferon Production and IRF7 Function in Sooty Mangabeys , 2013, PLoS pathogens.
[242] Geneviève Boucher,et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation , 2009, Nature Medicine.
[243] A. Lackner,et al. HIV swiftly guts the immune system , 2005, Nature Medicine.
[244] John W. Mellors,et al. Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.
[245] P. Lebon,et al. Primary infection with simian immunodeficiency virus: plasmacytoid dendritic cell homing to lymph nodes, type I interferon, and immune suppression. , 2008, Blood.
[246] R. Johnson,et al. Simian Immunodeficiency Virus Infection Induces Expansion of α4β7+ and Cytotoxic CD56+ NK Cells , 2010, Journal of Virology.
[247] Todd M. Allen,et al. HIV-1 adaptation to NK cell mediated immune pressure , 2011, Nature.
[248] R. Ribeiro,et al. Coagulation biomarkers predict disease progression in SIV-infected nonhuman primates. , 2012, Blood.
[249] E. Thiel,et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. , 2009, The New England journal of medicine.
[250] C. Rouzioux,et al. Elevated IP10 levels are associated with immune activation and low CD4+ T-cell counts in HIV controller patients , 2014, AIDS.
[251] T. Beddoe,et al. Killer cell immunoglobulin-like receptor 3DL1-mediated recognition of human leukocyte antigen B , 2011, Nature.
[252] A. Samri,et al. Specific Phenotypic and Functional Features of Natural Killer Cells From HIV-Infected Long-Term Nonprogressors and HIV Controllers , 2010, Journal of acquired immune deficiency syndromes.
[253] J. Hong,et al. Potential Mechanism for Viral Escape Infection : T / B Cell Homeostasis , Activation , during Simian Immunodeficiency Virus T Cells + Follicular Helper , B , and CD 8 T + Spatial Alterations between CD 4 , 2012 .
[254] J. Corbeil,et al. Simian Immunodeficiency Virus Infects Follicular Helper CD4 T Cells in Lymphoid Tissues during Pathogenic Infection of Pigtail Macaques , 2013, Journal of Virology.
[255] E. Rosenberg,et al. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction , 2007, Nature Immunology.
[256] Terri Wrin,et al. Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm , 2009, Journal of Virology.
[257] S. Elahi,et al. Protective HIV-specific CD8+ T cells evade Treg cell suppression , 2011, Nature Medicine.
[258] Michael D. George,et al. Th17 cells, HIV and the gut mucosal barrier , 2010, Current opinion in HIV and AIDS.